Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

246
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
246
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Cepheid Xpert Xpress CoV-2/Flu/RSV plus and the Biofire Spotfire R/ST Panel Mini using CLIA-waived devices.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2026
Same author

Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.

JNCI cancer spectrum·2026
Same author

Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications.

Current oncology (Toronto, Ont.)·2026
Same author

Nothing to Write Home About? A Scoping Review of Letters of Recommendation in the Match.

Medical science educator·2026
Same author

How does AI perform compared to human expert panels in medical Delphi studies? A pilot study through the lens of pathology.

Journal of pathology informatics·2026
Same author

Finding Holes: Pathologist-Level Performance Using AI for Cribriform Morphology Detection in Prostate Cancer.

European urology open science·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Oct 16, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

Paul Beinhoff1, Lavannya Sabharwal1,2,3, Vindhya Udhane1,2,3

  • 1Department of Pathology, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Cancers
|October 23, 2021
PubMed
Summary
This summary is machine-generated.

Androgen deprivation therapy resistance in prostate cancer (PC) can be overcome by targeting Jak2-Stat5 signaling. Jak2 inhibitors, particularly those active against wild-type Jak2, show promise for treating advanced PC.

Keywords:
Janus kinase 2 (Jak2)anti-androgen resistant prostate cancercastrate-resistant prostate cancer (CRPC)prostate cancer (PC)signal transducer and activator of transcription (Stat)solid tumors

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Related Experiment Videos

Last Updated: Oct 16, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer (PC), targeting androgen receptor (AR) pathways.
  • Castrate-resistant prostate cancer (CRPC) emerges due to AR reactivation, often becoming resistant to therapies like enzalutamide (ENZ).
  • Jak2-Stat5 signaling is implicated in PC progression and resistance to ENZ, making it a critical therapeutic target.

Purpose of the Study:

  • To review Jak2 inhibitors targeting both mutated (Jak2V617F) and wild-type (WT)-Jak2.
  • To assess the potential of these inhibitors for treating advanced prostate cancer, especially enzalutamide-resistant forms.

Main Methods:

  • Literature review of Jak2 inhibitors in development pipelines.
  • Analysis of Jak2 inhibitor activity against mutated Jak2V617F and WT-Jak2.
  • Evaluation of preclinical and clinical data on Jak2-Stat5 signaling in prostate cancer.

Main Results:

  • Jak2-Stat5 signaling drives enzalutamide-resistant prostate cancer growth.
  • Numerous Jak2 inhibitors are in development, with 35 compounds showing documented activity.
  • Inhibitors with potency against WT-Jak2 are particularly relevant for advanced PC therapy.

Conclusions:

  • Targeting Jak2-Stat5 signaling offers a promising strategy to overcome resistance to current prostate cancer therapies.
  • Jak2 inhibitors, especially those effective against WT-Jak2, represent a potential new therapeutic avenue for advanced and resistant prostate cancer.